Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 LabyrinthDepartment of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain; TERABIS Group, IBiS (Instituto de Biomedicina de Sevilla)/HUVR/CSIC/Universidad deSevilla), Sevilla, Spain.
Medizinische Abteilung, Zentrum für Onkologie und Hämatologie mit Ambulanz und alliativstation Wilhelminenspital, Vienna, Austria.
epartment of Clinical Oncology, Clinica San Carlo, Milan, Italy.
Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
Department of Clinical Oncology, University Hospital, Charles University-Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czechia.
Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia.
University Specialized Hospital for Active Treatment in Oncology, Medical Oncology Clinic, Sofia, Bulgaria; Medical University Pleven, Pleven, Bulgaria.
Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil; Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
University Hospital Centre, Zagreb Department of Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia.
Service de Radiothérapie Oncologique, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France.
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Department of Oncology, McMaster University Juravinski Cancer Centre, Hamilton, ON, Canada.
Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, United States.
Radiation Oncology Department, Jordanian Royal Medical Services, Amman, Jordan.
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Service d'Oncologie, GHT Grand Paris Nord-Est, Montfermeil, France.
Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece.
Show others and affiliations
2020 (English)In: Frontiers in Oncology, E-ISSN 2234-943X, Vol. 10, article id 575148
Article, review/survey (Refereed) Published
Abstract [en]
Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak.
Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies.
Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis.
Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.
Place, publisher, year, edition, pages
Frontiers , 2020. Vol. 10, article id 575148
Keywords [en]
Covid-19, international, oncology, recommendations, societies
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-88140DOI: 10.3389/fonc.2020.575148ISI: 000595107700001PubMedID: 33330049Scopus ID: 2-s2.0-85097297192OAI: oai:DiVA.org:oru-88140DiVA, id: diva2:1511308
2020-12-182020-12-182024-01-17Bibliographically approved